Chiasma (NASDAQ:CHMA) had its price target hoisted by HC Wainwright from $10.00 to $11.00 in a research report report published on Monday, The Fly reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.
A number of other equities research analysts also recently commented on the company. Zacks Investment Research downgraded Chiasma from a hold rating to a sell rating in a report on Thursday, March 19th. ValuEngine raised Chiasma from a hold rating to a buy rating in a research note on Thursday, March 5th. BidaskClub raised Chiasma from a hold rating to a buy rating in a research note on Tuesday, June 23rd. Finally, Cantor Fitzgerald reaffirmed an overweight rating on shares of Chiasma in a research note on Tuesday, March 17th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $11.70.
Chiasma stock opened at $4.51 on Monday. Chiasma has a one year low of $2.88 and a one year high of $9.25. The business has a fifty day moving average of $6.26 and a two-hundred day moving average of $5.00.
Several large investors have recently added to or reduced their stakes in the company. State Street Corp raised its stake in shares of Chiasma by 3.8% during the 1st quarter. State Street Corp now owns 621,227 shares of the biotechnology company’s stock worth $2,267,000 after buying an additional 22,703 shares during the last quarter. Vivo Capital LLC acquired a new position in Chiasma in the 1st quarter valued at about $4,643,000. Meeder Asset Management Inc. raised its stake in Chiasma by 799.9% in the 1st quarter. Meeder Asset Management Inc. now owns 7,190 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 6,391 shares during the last quarter. Invesco Ltd. raised its stake in Chiasma by 28.5% in the 1st quarter. Invesco Ltd. now owns 40,102 shares of the biotechnology company’s stock valued at $146,000 after purchasing an additional 8,902 shares during the last quarter. Finally, Ikarian Capital LLC raised its stake in Chiasma by 88.1% in the 1st quarter. Ikarian Capital LLC now owns 2,075,492 shares of the biotechnology company’s stock valued at $7,576,000 after purchasing an additional 972,195 shares during the last quarter. 75.24% of the stock is owned by institutional investors and hedge funds.
Chiasma Company Profile
Chiasma, Inc, a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.
Recommended Story: Momentum Indicator: Relative Strength Index
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.